Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Freya Meds vs Nucific

Freya Meds
Graded #364

Higher grade

vs+2.3999999999999986
Nucific
Graded #417

Lower grade

The verdict

Freya Meds takes it — 58.6/100 to 56.2/100.

Freya Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Freya Meds is a GLP-1 specialist offering compounded semaglutide ($250–$297/mo) and compounded tirzepatide ($332–$390/mo).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNucific +2
43
45
Dose & formulationFreya Meds +11
64
53
Clinical oversightNucific +5
71
76
Labs & monitoringFreya Meds +8
60
52
FulfillmentNucific +5
62
67
Contract termsFreya Meds +14
55
41
Freya Meds · left barNucific · right bar

The numbers

MetricFreya MedsNucific
WeighScore58.6/10056.2/100
GradeCC
Scorecard rank#364#417
Semaglutide$297/mo (compounded)Not disclosed
Tirzepatide$390/mo (compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Freya Meds

Graded #364 · C

Strengths

  • GLP-1 specialist — not a multi-category telehealth
  • Price includes unlimited doctor consultations, monthly group calls, and a dietitian consultation
  • Both semaglutide and tirzepatide available
  • Multi-month discount on quarterly billing
  • Claims 450,000+ enrolled

Where it loses points

  • No visible LegitScript or PCAB accreditation
  • Above-average pricing ($250–$390/mo)
  • Compounded only — no brand-name options
  • Now serves 49 U.S. states (one state excluded; specific exclusion not named)
Nucific

Graded #417 · C

Strengths

  • Founder is named and credentialed: Dr. Amy Lee, MD, triple board-certified in Internal Medicine, Obesity Medicine and Clinical Nutrition
  • Cites SURMOUNT-1 properly, naming the trial, the 20.9% average and the Jastreboff NEJM 2022 source
  • Discloses that featured patients were compensated for their time
  • Labels its NAD+ decline chart as illustrative and not a measurement, with an unusually careful methodology note
  • Offers compounded, microdosed and brand-name Ozempic and Zepbound in one catalogue

Where it loses points

  • No price is published anywhere; every option is gated behind a three-minute quiz
  • The LegitScript badge is a self-hosted image with generic alt text rather than the issued embed, so the certification could not be verified
  • A BBB Accredited A+ claim is displayed without a link to the BBB profile
  • No state list and no named pharmacy, only licensed U.S. pharmacies
  • Before-and-after photographs are used alongside compensated testimonials

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard